It has become increasingly apparent over recent years that micro-organisms of many kinds have evolved the capacity to subvert the host's immune response; in addition, a variety of mechanisms of subversion have been described [1] [2] [3] . For example, helminths coat themselves with host materials in order to hide their antigenic identity; other micro-organisms produce specific proteases to destroy antibody molecules in the bowel; and some bacteria -by mechanisms that are still not clear -prevent the insertion of the membrane-attack complex of complement into their plasma membranes. This complex is formed by the terminal components of the complement cascade, which provides an important arm of defence against extracellular pathogens.
Much recent interest has concentrated on the microbial production of proteins analogous to host protective factors, including the expression of complement control proteins and Fc receptors. One of the major surface glycoproteins of the Herpes simplex virus has complement receptor 1 (CR1) activity [4] , in that it binds to the complement proteins C3b and C4b, and vaccinia virus has been demonstrated to secrete a complement control protein [5] . Herpesvirus saimiri carries in its genome a gene encoding a protein that closely resembles the CD59 complement control protein of the squirrel monkey, its natural host [6] : the biological significance of this protein is not yet known but is currently under study [7] . Both trypanosomes and schistosomes are sensitive to complement-mediated lysis in the developmental stages outside the human host but rapidly become complement-resistant after invading the human host. It is now known that this acquisition of resistance is accompanied by the expression of specific proteins that have activities similar to those of the human complement control proteins CD59 and decay accelerating factor [8] . Candida albicans expresses a molecule resembling the integrin complement receptor CR3 which allows the organism to adhere to endothelium [9] . The expression of this CR3-like molecule is induced by the presence of glucose in the medium and is essential for the organism to grow systemically, therefore providing a clear example whereby a subverting molecule acts as an 'aggressin' -a factor promoting the virulence of a microorganism.
A novel and extremely subtle mechanism of invasion by mycobacteria has recently been described by Schorey et al. [10] . Pathogenic mycobacteria are intracellular parasites of macrophages and have acquired the capacity to enter macrophages through several classes of receptor expressed on the surface of macrophages: receptors for the C3 complement component (CR1, CR3 and CR4); mannose receptors; and class A scavenger receptors [11] . In order for complement-receptor-mediated entry to occur, however, the mycobacteria need to be coated with C3 fragments. Although this coating is normally achieved by activation of the alternative complement pathway, Schorey et al. [10] have identified another mechanism: the mycobacteria produce on their outer surface a protein that is functionally analogous to C4b in that it combines with a fragment of the complement protein C2. (The authors call this fragment C2a on historical grounds but, to conform with the conventions that govern the naming of complement fragments, it should be termed C2b -the larger cleavage product of C2 that contains its serine protease site. To be consistent with the Schorey paper, the name C2a is used in this dispatch for this larger C2 fragment.) The complex of the mycobacterial C4b-like protein and C2a forms a C3-converting enzyme (C3 convertase) on the membrane of the organism and allows the deposition of C3b onto its membrane. Bound C3b then promotes complement activation and amplifies the effects of the classical complement pathway, leading ultimately to invasion of the host macrophage by the mycobacterium.
It remains to be determined how closely the interaction of the mycobacterial protein with C2a resembles that of C4b and C2a (Figure 1) . The authors point out that C4b does not normally bind C2a from the fluid phase, although it does bind native C2. However, the early work on this topic [12, 13] was carried out before C4b was known to be rapidly broken down by the complement regulatory proteins, Factor I and C4-binding protein (C4bp) [14] . It may be the case that the mycobacterial C4b-like protein is resistant to such breakdown in a similar way to cobra venom factor, which behaves like a Factor I-resistant C3b protein. The paper does not reveal whether, like the interaction between C4b and C2, the interaction of the mycobacterial C4b-like protein with C2a requires magnesium. Also, the studies by Schorey et al. [10] do not show whether, in the presence of C3b, the enzyme formed on the surface of the mycobacteria can cleave C5 to initiate the formation of the membrane-attack complex -an interesting point as there is an allotype of human C4 (C4A6) which forms a C3 convertase with C2a but does not allow the cleavage of C5 [15] .
The C4b-like microbial protein has not yet been isolated and we therefore have no information about its structure. It is not known whether this protein is attached to the membrane via an amide or an ester linkage, in a similar way to the fixation mechanism of C4, and whether this protein has any sequence homology to C4 or C3. The reaction between C4b and C2a is also species-specific, like many of the 'lock and key' interactions of complement components, and it would be interesting to find out whether this reaction, which is reported to occur with horse serum as well as human serum, also occurs with other mammalian species. Does this mechanism of putting C3 fragments onto the mycobacterial surface have any advantage over the traditional method of alternative pathway activation? One possible benefit could be that the C3b fixed by this mechanism is less resistant to cleavage into its inactivated form, iC3b, by the complement control proteins Factor I and Factor H than C3b fixed by the alternative pathway in which the 'protected surface' hinders the action of Factor I. (C3b bound to the 'protected surface' is able to bind Factor B but is protected from binding Factor H.) This decreased resistance to cleavage could be important if the major receptors used for mycobacterial entry into macrophages are CR3 and CR4, because these leukocyte integrin receptors react only with iC3b and not with C3b itself. This explanation, however, is at variance with the data presented by the authors showing that CR1 is the major complement receptor used by Mycobacterium avium [10] . Another possible explanation is that the C2b capture mechanism may work at sites where there is insufficient plasma to support alternative pathway activation, which requires a high concentration of complement components.
A final point of interest with regard to these findings is that they provide a possible mechanism of selection that explains the relatively frequent occurrence of C2 deficiency in Caucasian populations. This deficiency is the most common complement deficiency in Caucasoids, but it is exceptionally rare in Black and Oriental populations [16] . The MHC haplotype that carries C2 deficiency has been conserved, suggesting that the deficiency can be attributed to a particular mutation that has been selected in the relatively recent past. It has often been proposed that the selective pressure in maintaining such mutations is to increase resistance to infectious diseases, and tuberculosis has been suggested as a selective agent for other mutations, such as those giving rise to α1 antitrypsin deficiency [17] and to cystic fibrosis [18] , which are common only in Caucasoids. Here, for the first time, we have a possible mechanism by which C2 deficiency might protect against tuberculosis and it is the first mechanism that has been proposed for any selective advantage for C2 deficiency. Schematic drawing of the part of the classical complement pathway that is relevant to the mycobacterial invasion mechanism described by Schorey et al. [10] . See text for details. C4c + C3d Current Biology
